Thermo Fisher Scientific

The PMSC, which formally opened last week, offers mass spectrometry and sequencing resources to help customers develop robust and scalable workflows.

With the release of its Q Exactive UHMR system and a new $130 million NIH program, the company sees opportunity to expand use of its cryo-EM and mass spec techs.

Major releases were relatively sparse at ASMS as many vendors focused instead on the development of applications and workflows for their existing platforms.

The firms will combine Thermo Fisher's mass spec systems with Evosep's liquid chromatography to develop high-throughput clinical proteomic methods.

Developed in the lab of Max Planck's Matthias Mann, the approach adjusts the sampling of ions during the initial scan to boost assay sensitivity and reproducibility.

Three vendors applied their variant calling and interpretation pipelines to the same tumor NGS panel data and came up with overlapping but different results.

The company announced agreements to use the Oncomine Dx Target Test in drug development programs with Daiichi Sankyo, Takeda, and Spectrum Pharmaceuticals.

The American Association for Cancer Research annual meeting wrapped up today in Chicago. Below are selected business briefs from the conference.

Pages

A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.

A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more